FDA Grants Priority Review to Keytruda as First-line Therapy for Advanced NSCLC

The U.S. Food and Drug Administration (FDA) has agreed to review Merck ‘s application seeking the extension of Keytruda ( pembrolizumab ) as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC). The supplemental Biologics License Application (sBLA) was granted priority review and a decision is expected […]

Leave a Reply